Cross-linked Hyaluronic Acid/dextranomer for the Treatment of Stress Urinary Incontinence

Launched by IZMIR BAKIRCAY UNIVERSITY · Sep 18, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new treatment for women who experience stress urinary incontinence (SUI), which is a condition where urine leaks during activities like coughing, sneezing, or exercising. The treatment being studied is an injection of a substance called cross-linked hyaluronic acid/dextranomer (CLHA/Dx) into the urethra, the tube that carries urine out of the body. The goal is to see if this treatment is effective and safe for helping women manage their incontinence.

To participate in this trial, women need to have a confirmed diagnosis of stress urinary incontinence and show that they experience leakage during specific tests. Some conditions that would exclude someone from participating include temporary incontinence, urinary infections, or certain mental health issues. The trial is currently not recruiting participants, but if you meet the eligibility criteria, you could expect to receive the injection and be monitored for its effects. This study is an important step in finding new solutions for women dealing with SUI.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of Stress Urinary Incontinence.
• • Presence of incontinence during the Valsalva maneuver.
• • Positive Marshall-Marchetti test result.
• • Post-void residual urine volume of ≤100 mL.
• Exclusion Criteria:
• • Temporary urinary incontinence.
• • Delirium.
• • Urinary tract infection.
• • Urethritis.
• • Pure urge incontinence.
• • Nocturnal enuresis.
• • Decreased bladder compliance or detrusor contraction observed in urodynamic -studies.
• • Leakage of urine with low bladder pressure.
• • Psychiatric conditions (severe depression and anxiety).
• • Body mass index (BMI) \> 35 kg/m².
• • Use of medications that may influence bladder storage or emptying.